Price
Frequently asked questions
What is Alector's market capitalization?
What is the Earnings Per Share (EPS) for Alector?
What are the analyst ratings and target price for Alector's stock?
What is Alector's revenue over the trailing twelve months?
What is the EBITDA for Alector?
What is the free cash flow of Alector?
What is the 5-year beta of Alector's stock?
How many employees does Alector have, and what sector and industry does it belong to?
What is the free float of Alector's shares?
Financials
Market Cap
$368.23M5Y beta
0.60EPS (TTM)
-$1.709Free Float
88.12MRevenue (TTM)
$61.51MEBITDA (TTM)
-$177.40MFree Cashflow (TTM)
-$222.26MPricing
Analyst Ratings
The price target is $13.75 and the stock is covered by 11 analysts.
Buy
8
Hold
2
Sell
1
Information
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration diseases. The Company is engaged in developing therapies designed to counteract these pathologies simultaneously by restoring healthy immune function to the brain. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration and immunology to identify immune system. Its product candidates: latozinemab (AL001), AL002, and AL101, are in clinical development. Its immune-neurology product candidates are supported by biomarkers and seek to treat indications, including Alzheimer’s disease and genetically defined frontotemporal dementia patient populations. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients.
241
Biotechnology & Drugs
Health Care
Identifier
ISIN
Primary Ticker